These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 31060333)

  • 1. Mito-Nuclear Communication in Hepatocellular Carcinoma Metabolic Rewiring.
    Mello T; Simeone I; Galli A
    Cells; 2019 May; 8(5):. PubMed ID: 31060333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects.
    Shang RZ; Qu SB; Wang DS
    World J Gastroenterol; 2016 Dec; 22(45):9933-9943. PubMed ID: 28018100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex and Race-Related DNA Methylation Changes in Hepatocellular Carcinoma.
    Ye W; Siwko S; Tsai RYL
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33917049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forcing ATGL expression in hepatocarcinoma cells imposes glycolytic rewiring through PPAR-α/p300-mediated acetylation of p53.
    Di Leo L; Vegliante R; Ciccarone F; Salvatori I; Scimeca M; Bonanno E; Sagnotta A; Grazi GL; Aquilano K; Ciriolo MR
    Oncogene; 2019 Mar; 38(11):1860-1875. PubMed ID: 30367149
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Li Y; Lin S; Li L; Tang Z; Hu Y; Ban X; Zeng T; Zhou Y; Zhu Y; Gao S; Deng W; Zhang X; Xie D; Yuan Y; Huang P; Li J; Cai Z; Guan XY
    Cancer Res; 2018 Aug; 78(16):4471-4481. PubMed ID: 29967258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.
    De Matteis S; Scarpi E; Granato AM; Vespasiani-Gentilucci U; La Barba G; Foschi FG; Bandini E; Ghetti M; Marisi G; Cravero P; Gramantieri L; Cucchetti A; Ercolani G; Santini D; Frassineti GL; Faloppi L; Scartozzi M; Cascinu S; Casadei-Gardini A
    Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30917505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
    Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
    J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eukaryotic translation initiation factor 5A2 promotes metabolic reprogramming in hepatocellular carcinoma cells.
    Cao TT; Lin SH; Fu L; Tang Z; Che CM; Zhang LY; Ming XY; Liu TF; Tang XM; Tan BB; Xiang D; Li F; Chan OY; Xie D; Cai Z; Guan XY
    Carcinogenesis; 2017 Jan; 38(1):94-104. PubMed ID: 27879277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-catenin-activated hepatocellular carcinomas are addicted to fatty acids.
    Senni N; Savall M; Cabrerizo Granados D; Alves-Guerra MC; Sartor C; Lagoutte I; Gougelet A; Terris B; Gilgenkrantz H; Perret C; Colnot S; Bossard P
    Gut; 2019 Feb; 68(2):322-334. PubMed ID: 29650531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD Related-HCC: The Relationship with Metabolic Disorders.
    Zhang X
    Adv Exp Med Biol; 2018; 1061():55-62. PubMed ID: 29956206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic heterogeneity of human hepatocellular carcinoma: implications for personalized pharmacological treatment.
    Berndt N; Eckstein J; Heucke N; Wuensch T; Gajowski R; Stockmann M; Meierhofer D; Holzhütter HG
    FEBS J; 2021 Apr; 288(7):2332-2346. PubMed ID: 33030799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma.
    Zhou X; Chen J; Yi G; Deng M; Liu H; Liang M; Shi B; Fu X; Chen Y; Chen L; He Z; Wang J; Liu J
    Oncotarget; 2016 Jan; 7(1):873-84. PubMed ID: 26621849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [β-catenin mutated hepatocarcinoma metabolic rewiring at the heart of their transformation].
    Senni N; Savall M; Bossard P
    Med Sci (Paris); 2018 Dec; 34(12):1029-1031. PubMed ID: 30623757
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver cancer cell lines distinctly mimic the metabolic gene expression pattern of the corresponding human tumours.
    Nwosu ZC; Battello N; Rothley M; Piorońska W; Sitek B; Ebert MP; Hofmann U; Sleeman J; Wölfl S; Meyer C; Megger DA; Dooley S
    J Exp Clin Cancer Res; 2018 Sep; 37(1):211. PubMed ID: 30176945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathway crosstalk analysis of microarray gene expression profile in human hepatocellular carcinoma.
    Zhou X; Zheng R; Zhang H; He T
    Pathol Oncol Res; 2015 Jul; 21(3):563-9. PubMed ID: 25480734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GlcNAcylation on Rab3A attenuates its effects on mitochondrial oxidative phosphorylation and metastasis in hepatocellular carcinoma.
    Wu W; Zheng X; Wang J; Yang T; Dai W; Song S; Fang L; Wang Y; Gu J
    Cell Death Dis; 2018 Sep; 9(10):970. PubMed ID: 30237463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nek2 augments sorafenib resistance by regulating the ubiquitination and localization of β-catenin in hepatocellular carcinoma.
    Deng L; Sun J; Chen X; Liu L; Wu D
    J Exp Clin Cancer Res; 2019 Jul; 38(1):316. PubMed ID: 31319849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of the lysophosphatidic acid signaling axis in liver cancer.
    Lopane C; Agosti P; Gigante I; Sabbà C; Mazzocca A
    Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):277-282. PubMed ID: 28591560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical or genetic Pin1 inhibition exerts potent anticancer activity against hepatocellular carcinoma by blocking multiple cancer-driving pathways.
    Liao XH; Zhang AL; Zheng M; Li MQ; Chen CP; Xu H; Chu QS; Yang D; Lu W; Tsai TF; Liu H; Zhou XZ; Lu KP
    Sci Rep; 2017 Mar; 7():43639. PubMed ID: 28262728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.